Gold Sponsors
Dexcom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Advocacy Sponsor
We’re a medicine company turning science into healing to make life better for people around the world.
Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world’s most significant health challenges. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: “Take what you find here and make it better and better.”
But we’re not only dedicated to making medicines. We go beyond medicine to deliver innovative clinical trials that reflect the diversity of our world and work to ensure our medicines are accessible and affordable. Learn more at www.lilly.com/who-we-are/about-lilly.
Silver Sponsors
Tandem Diabetes Care creates new possibilities for people living with diabetes, their loved ones, and their healthcare providers through a positively different experience. We deliver innovative products and automated insulin delivery systems — including Tandem Mobi and the t:slim X2 — to people who require insulin therapy. For more information, visit tandemdiabetes.com.
Bronze Sponsors
The Diabetes Patient Advocacy Coalition (DPAC) is an alliance of people with diabetes, caregivers, patient advocates, health professionals, diabetes organizations and companies working collaboratively to promote and support public policy initiatives to improve the health of all 37.3 million Americans with diabetes. We train people in the diabetes community on how to be advocates for themselves and their families. We work to ensure quality of and access to care, medications, and devices for patients living with diabetes; and to educate, inspire, and empower patient advocates as well as lawmakers toward meaningful action on diabetes.
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and, in February 2024, was granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group – in a large-scale meta-analysis and in the Company’s European Phase IIb trial, where Diamyd® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes.
Xeris Pharmaceuticals, Inc., the maker of Gvoke HypoPen® (glucagon injection), is dedicated to unlocking the potential of glucagon. We believe that our technology can have a profound impact on the lives of patients and their families. That’s why we are proud to be the first to develop liquid glucagon, but that’s just the beginning. We’re also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue solutions that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com
